Digitalis inhibits and furosemide does not change the in vitro phagocytic function of neutrophils of healthy subjects

International Immunopharmacology

Volumn 3, Issue 10-11, 2003, Pages 1439-1445

  Muniz Junqueira, Maria Imaculada ^a   Mota, Lícia Maria ^a   Aires, Rodrigo Barbosa ^a   Junqueira Jr , Luiz Fernando ^b  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

Author keywords

Digitalis; Furosemide; Heart failure; Neutrophils; Phagocytosis

Indexed keywords

DESLANOSIDE; DIGITALIS; FUROSEMIDE;

ADULT; ARTICLE; BLOOD CELL; CELL COUNT; CELL FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; EVALUATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INGESTION; INHIBITION KINETICS; MALE; NEUTROPHIL; NORMAL HUMAN; PHAGOCYTOSIS; RANK SUM TEST; SACCHAROMYCES CEREVISIAE; YEAST;

EID: 0042427638     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00142-5     Document Type: Article

References (39)

1. Gotschlich E.C. Immunity to extracellular bacteria. Paul W.E. Fundamental immunology. 1993;1287-1308 Raven Press, New York.
2. Lekstrom-Himes J.A., Gallin J.I. Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med. 343:2000;1703-1714.
3. Shearer W.T., Anderson D.C. The secondary immunodeficiencies. Stiehm E.R. Immunological disorders in infants and children. 1989;400-438 Saunders, Philadelphia.
4. Underhill D.M., Ozinsky A. Phagocytosis of microbes. Complexity in action. Annu. Rev. Immunol. 20:2002;825-852.
5. Esposito A.L., Poirier W.J., Clark C.A. The cardiac glycoside digoxin disrupts host defense in experimental pneumococcal pneumonia by impairing neutrophil mobilization. Am. Rev. Respir. Dis. 140:1989;1590-1594.
6. Mason D.T. Digitalis pharmacology and therapeutics: recent advances. Ann. Intern. Med. 80:1974;520-530.
7. Yuengsrigul A., Chin T.W., Nussbaum E. Immunosupressive and cytotoxic effects of furosemide on human peripheral blood mononuclear cells. Ann. Allergy Asthma Immunol. 83:1999;559-566.
8. Simchowitz L., De Weer P. Chloride movements in human neutrophils. Diffusion, exchange, and active transport. J. Gen. Physiol. 88:1986;167-194.
9. Fedson D.S., Chiarello L.A. Previous hospital care and pneumococcal bacteremia. Importance for pneumococcal immunization. Arch. Intern. Med. 143:1983;885-889.
10. Braunwald E., Grossman W. Clinical aspects of heart failure. Braunwald E. Heart disease. 1992;444-463 Saunders, Philadelphia.
11. Farr B.M., Woodhead M.A., Macfarlane J.T., Bartlett C.L.R., McCracken J.S., Wadsworth J.et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir. Med. 94:2000;422-427.
12. Farr B.M., Bartlett C.L.R., Wadsworth J., Miller D.L. Risk factor for community-acquired pneumonia diagnosed upon hospital admission. Respir. Med. 94:2000;954-963.
13. Esposito A.L. Digoxin disrupts the inflammatory response in experimental pneumococcal pneumonia. J. Infect. Dis. 152:1985;14-23.
14. Esposito A.L. Community-acquired bacteremic pneumococcal pneumonia. Effects of age on manifestations and outcome. Arch. Intern. Med. 144:1984;945-948.
15. Brandi MCAC. Padronização de um método de obtenção de fagócitos do sangue periférico para avaliação funcional. Thesis, Universidade de Brasília, Brasília, DF; 1993.
16. Bakke O.M., Aslaksen A., Lehmann V., Lien E. Pharmacokinetics and serum concentration-effect relationship of intravenous deslanoside. J. Cardiovasc. Pharmacol. 3:1981;1015-1025.
17. Ponto L.L.B., Schoenwald R.D. Furosemide. A pharmacokinetic/pharmacodynamic review. Clin. Pharmacokinet. 18:1990;381-408.
18. Muniz-Junqueira M.I., Prata A., Tosta C.E. Phagocytic and bactericidal function of mouse macrophages to Salmonella typhimurium in schistosomiasis mansoni. Am. J. Trop. Med. Hyg. 46:1992;132-136.
19. Myrick J.E., Hannon W.H. A model system for radioimmunoassays: digoxin reference method. Rose N.R., Macario E.C., Folds J.D., Lane C., Nakamura R.M. Manual of clinical laboratory immunology. 1997;30-38 ASM, Washington.
20. Moe G.K., Farah A.E. Digitalis and allied cardiac glycosides. Goodman L.S., Gilman A. The pharmacological basis of therapeutics. 1970;677-708 Collier-Macmillan, London.
21. Mollinedo F., Borregaard N., Boxer L.A. Novel trends in neutrophil structure, function and development. Trends Immunol. 12:1999;535-537.
22. Mühlberg W., Platt D., Neubig E. Pharmacokinetics and pharmacodynamics of furosemide in geriatric patients. Arch. Gerontol. Geriatr. 5:1986;249-263.
23. Lachmann P.J., Hobart M.J. Complement technology. Weir D.M. Handbook of experimental immunology: I. Immunochemistry. 1978;1A-5A Blackwell, Oxford.
24. Esposito A.L., Clark C.A., Poirier W.J. The cardiac glycoside digoxin does not alter the activity of human polymorphonuclear leukocytes in vitro. J. Infect. Dis. 157:1988;1084-1087.
25. Blum A., Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu. Rev. Med. 52:2001;15-27.
26. Mann D.L., Deswal A., Bozkurt B., Torre-Amione G. New therapeutics for chronic heart failure. Annu. Rev. Med. 53:2002;59-74.
27. Muniz-Juqueira M.I., Santos-Neto L.L., Tosta C.E. Influence of tumor necrosis factor-α on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell. Immunol. 208:2001;73-79.
28. van Vlem B., Vanholder R., De Paepe P., Vogelaers D., Ringoir S. Immunomodulating effects of antibiotics: literature review. Infection. 24:1996;275-291.
29. Epstein F.H. Cardiovascular disease epidemiology. A journey from the past into the future. Circulation. 93:1996;1755-1764.
30. Sharpe N., Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet. 352(Suppl.):1998;3-7.
31. Mendez G.F., Cowie M.R. The epidemiological features of heart failure in developing countries: a review of the literature. Int. J. Cardiol. 80:2001;213-219.
32. Kierszenbaum F. Chagas' disease and the autoimmune hypothesis. Clin. Microbiol. Rev. 12:1999;210-223.
33. Ludewig B., Zinkernagel R.M., Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc. Med. 12:2002;154-159.
34. Guilherme L., Kalil J. Rheumatic fever: the T cell response leading to autoimmune aggression in the heart. Autoimmun. Rev. 1:2002;261-266.
35. Cleland J.G.F., Swedberg K., Poole-Wilson P.A. Successes and failures of current treatment of heart failure. Lancet. 352(Suppl.):1998;19-28.
36. Ginaldi L., De Martinis M., D'Ostilio A., Marini L., Loreto M.F., Quaglino D. Immunological changes in the elderly. Aging Clin. Exp. Res. 11:1999;281-286.
37. Malaguarnera L., Ferlito L., Imbesi R.M., Gulizia G.S., Di Mauro S., Maugeri D.et al. Immunosenescence: a review. Arch. Gerontol. Geriatr. 32:2001;1-14.
38. Lord J.M., Butcher S., Killampali V., Lascelles D., Salmon M. Neutrophil ageing and immunosenescence. Mech. Ageing Dev. 122:2001;1521-1535.
39. Lip G.Y.H., Gibbs C.R., Beevers D.G. ABC of heart failure: aetiology. BMJ. 320:2000;104-107.